Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clindamycin phosphate + butoconazole nitrate is a fixed-dose combination of two active pharmaceutical ingredients used for the treatment of vaginal infections. Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of bacterial ribosomes, thereby impeding peptide chain initiation and elongation, which results in bacteriostatic or bactericidal activity depending on concentration and organism susceptibility[2][8]. It is primarily indicated for bacterial vaginosis. Butoconazole nitrate is an azole antifungal agent that works by inhibiting ergosterol synthesis in fungal cell membranes, leading to increased membrane permeability and cell death; it is primarily indicated for vulvovaginal candidiasis[7]. The combination would theoretically provide broad-spectrum coverage against both bacterial (bacterial vaginosis) and fungal (yeast) vaginal infections, though no specific co-formulated product appears widely marketed or referenced in major drug databases as of now.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin phosphate + butoconazole nitrate.